HealthdirectFree Australian health advice you can count on.

( ARTG ) Nebcin is indicated for the treatment of the following serious infections caused by susceptible micro-organisms: central nervous system infections, including meningitis, septicaemia and neonatal sepsis; gastrointestinal infections, including peritonitis; and other such significant infections as: complicated and recurrent urinary tract infections, such as pyelonephritis and cystitis; lower respiratory tract infections, including pneumonia, bronchopneumonia, and acute bronchitis; skin, bone and soft-tissue infections, including burns.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ Aminoglycosides, including Nebcin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Nebcin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated, and when bacterial susceptibility testing and clinical judgement indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to Nebcin. If susceptibility tests show that the causative organism is resistant to Nebcin, other appropriate therapy should be instituted. In patients in whom gram-negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, Nebcin therapy may be initiated before results of susceptibility studies are obtained. The decision to continue Nebcin therapy should be based upon the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed under WARNINGS.